Compare SQNS & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | KYNB |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 32.8M |
| IPO Year | 2011 | 2014 |
| Metric | SQNS | KYNB |
|---|---|---|
| Price | $2.49 | $3.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.33 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 65.2K | 23.3K |
| Earning Date | 11-03-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,440,000.00 |
| Revenue This Year | $24.60 | N/A |
| Revenue Next Year | $68.32 | $14.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $3.50 |
| 52 Week High | $6.98 | $9.66 |
| Indicator | SQNS | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 27.82 |
| Support Level | $2.37 | N/A |
| Resistance Level | $3.15 | $7.41 |
| Average True Range (ATR) | 0.16 | 0.39 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 17.74 | 15.72 |
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.